Podchaser Logo
Home
Targeted TalksEpisode from the podcastTargeted Talks
Next Episode
FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

Released Friday, 15th March 2024
Good episode? Give it some love!
FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

Friday, 15th March 2024
Good episode? Give it some love!
Rate Episode
About
InsightsPodchaser Pro
Reviews
Credits
Lists
Transcript

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Show More
Rate
Get this podcast via API

From The Podcast

Targeted Talks

6
Targeted Oncology brings you Targeted Talks, a monthly podcast featuring discussions with academic and community oncologists surrounding advancements in cancer research and best practices for patient management.

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features
Podchaser Logo

Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More